EP1476137A1 - Composition comprising low water soluble compounds within porous carriers - Google Patents
Composition comprising low water soluble compounds within porous carriersInfo
- Publication number
- EP1476137A1 EP1476137A1 EP03734705A EP03734705A EP1476137A1 EP 1476137 A1 EP1476137 A1 EP 1476137A1 EP 03734705 A EP03734705 A EP 03734705A EP 03734705 A EP03734705 A EP 03734705A EP 1476137 A1 EP1476137 A1 EP 1476137A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- low water
- active compound
- support material
- membrane
- biologicauy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 140
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 239000000969 carrier Substances 0.000 title description 3
- 239000000463 material Substances 0.000 claims abstract description 86
- 239000011148 porous material Substances 0.000 claims abstract description 61
- 150000002632 lipids Chemical class 0.000 claims description 70
- 239000012528 membrane Substances 0.000 claims description 60
- 239000004094 surface-active agent Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 43
- 239000002904 solvent Substances 0.000 claims description 41
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 36
- 239000002537 cosmetic Substances 0.000 claims description 23
- 239000002552 dosage form Substances 0.000 claims description 22
- 239000006185 dispersion Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 12
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 238000011068 loading method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000011877 solvent mixture Substances 0.000 claims description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229910000171 calcio olivine Inorganic materials 0.000 claims description 4
- 239000007970 homogeneous dispersion Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 235000004443 Ricinus communis Nutrition 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052681 coesite Inorganic materials 0.000 claims description 2
- 229910052906 cristobalite Inorganic materials 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229910052682 stishovite Inorganic materials 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229910052905 tridymite Inorganic materials 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 229910021534 tricalcium silicate Inorganic materials 0.000 claims 1
- -1 cyclosporin A or G Natural products 0.000 description 101
- 239000003814 drug Substances 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 35
- 239000002245 particle Substances 0.000 description 34
- 238000004090 dissolution Methods 0.000 description 33
- 229940079593 drug Drugs 0.000 description 32
- 150000003904 phospholipids Chemical class 0.000 description 31
- 235000014113 dietary fatty acids Nutrition 0.000 description 25
- 239000000194 fatty acid Substances 0.000 description 25
- 229930195729 fatty acid Natural products 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 239000000843 powder Substances 0.000 description 23
- 239000000725 suspension Substances 0.000 description 22
- 229920000223 polyglycerol Polymers 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 16
- 239000002775 capsule Substances 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 229940106189 ceramide Drugs 0.000 description 14
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical group OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 11
- 150000001783 ceramides Chemical class 0.000 description 11
- 239000008180 pharmaceutical surfactant Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- WOKDXPHSIQRTJF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO WOKDXPHSIQRTJF-UHFFFAOYSA-N 0.000 description 10
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 10
- 108010036949 Cyclosporine Proteins 0.000 description 10
- 229930186217 Glycolipid Natural products 0.000 description 10
- 229960001265 ciclosporin Drugs 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 229930105110 Cyclosporin A Natural products 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 9
- 235000010445 lecithin Nutrition 0.000 description 9
- 239000000787 lecithin Substances 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000002634 lipophilic molecules Chemical class 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229920000136 polysorbate Chemical class 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 150000003408 sphingolipids Chemical class 0.000 description 6
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 5
- 229940122440 HIV protease inhibitor Drugs 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 5
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 235000012241 calcium silicate Nutrition 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 239000004030 hiv protease inhibitor Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 4
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 102000004300 GABA-A Receptors Human genes 0.000 description 4
- 108090000839 GABA-A Receptors Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 4
- 239000004147 Sorbitan trioleate Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000378 calcium silicate Substances 0.000 description 4
- 229960003340 calcium silicate Drugs 0.000 description 4
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 4
- 229930183167 cerebroside Natural products 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000007771 core particle Substances 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000005313 fatty acid group Chemical group 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 150000002270 gangliosides Chemical class 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000002482 oligosaccharides Polymers 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229940068965 polysorbates Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 229940035044 sorbitan monolaurate Drugs 0.000 description 4
- 235000011069 sorbitan monooleate Nutrition 0.000 description 4
- 239000001593 sorbitan monooleate Substances 0.000 description 4
- 229940035049 sorbitan monooleate Drugs 0.000 description 4
- 235000019337 sorbitan trioleate Nutrition 0.000 description 4
- 229960000391 sorbitan trioleate Drugs 0.000 description 4
- 235000011078 sorbitan tristearate Nutrition 0.000 description 4
- 239000001589 sorbitan tristearate Substances 0.000 description 4
- 229960004129 sorbitan tristearate Drugs 0.000 description 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 3
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 3
- 230000000274 adsorptive effect Effects 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 150000001784 cerebrosides Chemical class 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000012943 hotmelt Substances 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 150000008495 β-glucosides Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 2
- SVJMLYUFVDMUHP-MGBGTMOVSA-N (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-MGBGTMOVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AVZIYOYFVVSTGQ-RBWRNIRVSA-N (z)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O AVZIYOYFVVSTGQ-RBWRNIRVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 108010010369 HIV Protease Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 229910052593 corundum Inorganic materials 0.000 description 2
- 108010019249 cyclosporin G Proteins 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002706 gusperimus Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 2
- 239000008389 polyethoxylated castor oil Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000006208 topical dosage form Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229910001845 yogo sapphire Inorganic materials 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- OITXQULUNSCKPV-GQHWWOMESA-N (2E,4E,6E)-7-[(2R,3R,5R)-5-[(4E,6E)-8-[[2-[(2R,3R,4R,6S)-2,3-dihydroxy-5,5-dimethyl-6-[(1E,3Z)-penta-1,3-dienyl]-4-(2-phenylacetyl)oxyoxan-2-yl]-3-[(2S,4R,5S,6R)-5-[(2S,4S,5R,6R)-5-[(2R,4R,5S,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxypropanoyl]amino]-3-methoxy-4-methylocta-4,6-dien-2-yl]-3-hydroxyoxolan-2-yl]hepta-2,4,6-trienoic acid (2E,4E,6E)-7-[(2R,3R,5R)-5-[(4E,6E)-8-[[2-[(2R,3R,4R,6S)-2,4-dihydroxy-5,5-dimethyl-6-[(1E,3Z)-penta-1,3-dienyl]-3-(2-phenylacetyl)oxyoxan-2-yl]-3-[(2S,4R,5S,6R)-5-[(2S,4S,5R,6R)-5-[(2R,4R,5S,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxypropanoyl]amino]-3-methoxy-4-methylocta-4,6-dien-2-yl]-3-hydroxyoxolan-2-yl]hepta-2,4,6-trienoic acid Chemical compound COC(C(C)[C@H]1C[C@@H](O)[C@H](O1)\C=C\C=C\C=C\C(O)=O)C(\C)=C\C=C\CNC(=O)C(CO[C@@H]1C[C@@H](OC)[C@@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3C[C@@H](OC)[C@@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)[C@@]1(O)O[C@@H](\C=C\C=C/C)C(C)(C)[C@@H](OC(=O)Cc2ccccc2)[C@H]1O.COC(C(C)[C@H]1C[C@@H](O)[C@H](O1)\C=C\C=C\C=C\C(O)=O)C(\C)=C\C=C\CNC(=O)C(CO[C@@H]1C[C@@H](OC)[C@@H](O[C@H]2C[C@H](OC)[C@H](O[C@@H]3C[C@@H](OC)[C@@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)[C@@]1(O)O[C@@H](\C=C\C=C/C)C(C)(C)[C@@H](O)[C@H]1OC(=O)Cc1ccccc1 OITXQULUNSCKPV-GQHWWOMESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- NYJVPTKMDYSZDU-MRNVWEPHSA-N (2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 NYJVPTKMDYSZDU-MRNVWEPHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-ANOYILKDSA-N (3s,8r,9s,10s,13r,14s,17r)-17-[(2r,5s)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical class C1CC2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 LGJMUZUPVCAVPU-ANOYILKDSA-N 0.000 description 1
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- IIZBNUQFTQVTGU-PTTKHPGGSA-N (z)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O IIZBNUQFTQVTGU-PTTKHPGGSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1.OC(=O)C(O)C1=CC=CC=C1 QBYIENPQHBMVBV-UHFFFAOYSA-N 0.000 description 1
- ULHLNVIDIVAORK-UHFFFAOYSA-N 2-hydroxybutanedioic acid Chemical compound OC(=O)C(O)CC(O)=O.OC(=O)C(O)CC(O)=O ULHLNVIDIVAORK-UHFFFAOYSA-N 0.000 description 1
- OPPHZZJEDWTNHQ-UHFFFAOYSA-N 2-hydroxypropanoyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O OPPHZZJEDWTNHQ-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- OORRCVPWRPVJEK-UHFFFAOYSA-N 2-oxidanylethanoic acid Chemical compound OCC(O)=O.OCC(O)=O OORRCVPWRPVJEK-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical compound N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- GGVUNNUOJDGCBK-UHFFFAOYSA-N 3-o-methyl 5-o-(oxolan-2-ylmethyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC2OCCC2)C1C1=CC=CC=C1[N+]([O-])=O GGVUNNUOJDGCBK-UHFFFAOYSA-N 0.000 description 1
- MRBKEAMVRSLQPH-UHFFFAOYSA-N 3-tert-butyl-4-hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1 MRBKEAMVRSLQPH-UHFFFAOYSA-N 0.000 description 1
- AAALVYBICLMAMA-UHFFFAOYSA-N 4,5-dianilinophthalimide Chemical compound C=1C=CC=CC=1NC=1C=C2C(=O)NC(=O)C2=CC=1NC1=CC=CC=C1 AAALVYBICLMAMA-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- AERBNCYCJBRYDG-RGBJRUIASA-N 4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCC(O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-RGBJRUIASA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- PFXXWXGYPMVYAN-UHFFFAOYSA-N C(C)C(CCCCCCCCCCCCC)[N+](C)(C)Cl Chemical compound C(C)C(CCCCCCCCCCCCC)[N+](C)(C)Cl PFXXWXGYPMVYAN-UHFFFAOYSA-N 0.000 description 1
- NFMLYFQBTFGSCR-UHFFFAOYSA-N C(C)C(CCCCCCCCCCCCCCCCC)[N+](C)(C)Cl Chemical compound C(C)C(CCCCCCCCCCCCCCCCC)[N+](C)(C)Cl NFMLYFQBTFGSCR-UHFFFAOYSA-N 0.000 description 1
- RTGLAMRJKFKJAC-UHFFFAOYSA-N C(C)C[N+](C)(CCCCCCCCCCCC)Cl Chemical compound C(C)C[N+](C)(CCCCCCCCCCCC)Cl RTGLAMRJKFKJAC-UHFFFAOYSA-N 0.000 description 1
- WNZWOXSPWYQIAH-UHFFFAOYSA-N C(CCCCCCCCCCC)C[N+](C)(C)Cl Chemical compound C(CCCCCCCCCCC)C[N+](C)(C)Cl WNZWOXSPWYQIAH-UHFFFAOYSA-N 0.000 description 1
- PLXWPHOFVYUMSV-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)C[N+](C)(C)Cl Chemical compound C(CCCCCCCCCCCCCCC)C[N+](C)(C)Cl PLXWPHOFVYUMSV-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- MGHCYDSTENLLSC-UHFFFAOYSA-N CC(C)(C)CCCCCCCCCCCCCCCCCNCl Chemical compound CC(C)(C)CCCCCCCCCCCCCCCCCNCl MGHCYDSTENLLSC-UHFFFAOYSA-N 0.000 description 1
- JKSVUWJVQWDWHN-UHFFFAOYSA-N CC(C)(C)CCCCCCCCCCCCCNCl Chemical compound CC(C)(C)CCCCCCCCCCCCCNCl JKSVUWJVQWDWHN-UHFFFAOYSA-N 0.000 description 1
- PSQZURIOAGQANZ-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC PSQZURIOAGQANZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940126544 HIV-1 protease inhibitor Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 108010016191 Human immunodeficiency virus 2 p16 protease Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- MMQZBEXYFLXHEN-UHFFFAOYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O MMQZBEXYFLXHEN-UHFFFAOYSA-N 0.000 description 1
- RUSIZKKQGFQEHZ-UHFFFAOYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RUSIZKKQGFQEHZ-UHFFFAOYSA-N 0.000 description 1
- WTAYIFXKJBMZLY-XZABIIKCSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O WTAYIFXKJBMZLY-XZABIIKCSA-N 0.000 description 1
- BXFIYCSMCYTCPN-IRCKQMGYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O BXFIYCSMCYTCPN-IRCKQMGYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 244000133018 Panax trifolius Species 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- FCASKLHVRFDIJB-UHFFFAOYSA-N Riboflavine Natural products Cc1cc2N=C3C(NC(=O)NC3=O)N(CC(O)C(O)C(O)CO)c2cc1C FCASKLHVRFDIJB-UHFFFAOYSA-N 0.000 description 1
- QTLQVMGAXZJADU-ZRWMMNBYSA-N Rifamexil Chemical compound S1C(N(CC)CC)=NC(C2=C(C(O)=C3C)C=4O)=C1C=4NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC3=C2C1=O QTLQVMGAXZJADU-ZRWMMNBYSA-N 0.000 description 1
- SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
- PALZHOJEQDADJU-UHFFFAOYSA-N [2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]propyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COC(=O)CCCCCCCCCCCCCCCCC PALZHOJEQDADJU-UHFFFAOYSA-N 0.000 description 1
- XJXFLRWMYHIIKV-CLFAGFIQSA-N [2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propoxy]propyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COC(=O)CCCCCCC\C=C/CCCCCCCC XJXFLRWMYHIIKV-CLFAGFIQSA-N 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- OGELJRHPEZALCC-UHFFFAOYSA-N [3-(2,3-dihydroxypropoxy)-2-hydroxypropyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)COCC(O)CO OGELJRHPEZALCC-UHFFFAOYSA-N 0.000 description 1
- JHSNLCCMZMGXLK-UHFFFAOYSA-N [3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO JHSNLCCMZMGXLK-UHFFFAOYSA-N 0.000 description 1
- NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 description 1
- NGHUOSKIZOQGBY-PMDAXIHYSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(COC(=O)CCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCC\C=C/CCCCCCCC)OC(=O)CCCCCCC\C=C/CCCCCCCC NGHUOSKIZOQGBY-PMDAXIHYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 239000001546 cuminum cyminum l. fruit oil Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- RGOLHHQRNQPCOF-UHFFFAOYSA-N decanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.CCCCCCCCCC(O)=O RGOLHHQRNQPCOF-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 description 1
- 229950002422 dexniguldipine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- OGPWIDANBSLJPC-RFPWEZLHSA-N diflucortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O OGPWIDANBSLJPC-RFPWEZLHSA-N 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 1
- 229960004318 dihydroergocristine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 125000004016 elaidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-M ethyl sulfate Chemical compound CCOS([O-])(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-M 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229950005851 furnidipine Drugs 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 125000000644 gadoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950005153 ganefromycin Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000000625 hexosyl group Chemical group 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000403 lignoceroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 150000002664 lycopenes Chemical class 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002037 methylprednisolone aceponate Drugs 0.000 description 1
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 1
- MJVGBKJNTFCUJM-UHFFFAOYSA-N mexenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(C)C=C1 MJVGBKJNTFCUJM-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Chemical class 0.000 description 1
- 235000010935 mono and diglycerides of fatty acids Nutrition 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 125000000265 myristoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RHIIHYCQYFKTHL-UHFFFAOYSA-N n,n'-dihexadecyl-n,n'-bis(2-hydroxyethyl)propanediamide Chemical compound CCCCCCCCCCCCCCCCN(CCO)C(=O)CC(=O)N(CCO)CCCCCCCCCCCCCCCC RHIIHYCQYFKTHL-UHFFFAOYSA-N 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229950010800 niguldipine Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000001320 petroselaidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000001955 polyclycerol esters of fatty acids Substances 0.000 description 1
- 235000010963 polyclycerol esters of fatty acids Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910021426 porous silicon Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 229950003551 ramoplanin Drugs 0.000 description 1
- 108010076689 ramoplanin Proteins 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229950003607 rifamexil Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960003320 roxatidine Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229940083492 sitosterols Drugs 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- QDZIHWBJFUNKOF-UHFFFAOYSA-N teloxantrone Chemical compound OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC QDZIHWBJFUNKOF-UHFFFAOYSA-N 0.000 description 1
- 229950010138 teloxantrone Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229950001463 thymoctonan Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 description 1
- 229960000832 tromantadine Drugs 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 125000003847 vaccenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Definitions
- the present invention relates to compositions for improving the solubility or dispersibility of biologically active compounds having low water solubility in molecular association or in ultra fine form.
- a specific object of the invention is to improve the dissolution rate or dispersive properties of a lipophilic compound with low water solubility and its bioavailability, without using energy intensive methods for particle size reduction or relying on the presence of high levels of solvents in the composition.
- a major benefit of the present invention is that extensive milling procedures, such as wet-milling to obtain sub-micron drug particles are avoided.
- the lipophilic compound is in ultra fine form with large surface areas with improved dispersibility and increased dissolution profile compared to micronised drug particles.
- the biologically active compound with low water solubility is held inside the pores of a suitable support material in association or solution in a suitable membrane lipid and/ or surfactant or is present as ultrathin layer(s) and/ or ultrafine amorphous particles with or without lipid and/ or surfactant.
- the compositions may be further processed into suitable dosage forms, such as semi-solid and solid dosage forms, with minimum effort.
- Improvement of dispersibility and dissolution rates employ size reduction methods for obtaining small particles of water insoluble compounds, and/ or require fillers, diluents, anti- caking and adsorptive aids to stabilise the external surfaces of micronised drug particles to prevent agglomeration.
- energy mills are used to micronise active materials with the aim of improving solubility from the large external surface areas created. Preventing clumping and crystal growth of micronised or precipitated particles is a problem and in reality the methods often fail to produce significant increases in bioavailability.
- US-A-5,091,188 discloses injectable compositions in which insoluble or poorly soluble drugs in powder form are stabilized against agglomeration during storage by treating the external surface of the particles with one or more layers of phospholipid.
- WO 99/49846 discloses compositions and procedures that yield sub-micron and micron size stable crystalline particles of water-insoluble drugs.
- the surfaces are treated with phospholipid, a charged surface modifier and a block copolymer.
- high shear mixing with multiple passes through a micro fluidiser is necessary to produce particles of sufficiently small size.
- WO 99/65469 further discloses submicron particles of water-insoluble drugs, prepared simultaneously by stabilising microparticulate suspensions of the drug with surface modifier molecules e.g. a phospholipid, by rapid expansion into an aqueous medium from a compressed solution of the compound and surface modifiers in a liquified gas.
- the particles of the drug are surface stabilised in the suspension in order to prevent agglomeration.
- EP-A-0 795 585 discloses a process for preparing finely divided particulate suspensions of a retinoid or carotenoid in a volatile, organic solvent mixed with aqueous medium in the presence of a physiologically compatible emulsifying agent, e.g. lecithin.
- the prior art also describes methods of preparing co-precipitates with or without lipids with the aim of improving solubility.
- preparation of lipid-drug co-precipitates using diacyl phospholipids to increase the dissolution behaviour of poorly water soluble drug solvates, and the possibility of modifying drug release from such dispersions by incorporating small amounts( ⁇ 0.05%) of poly vinyl pyrrolidone is described in J. Pharm. Sci. 81, 283-286 (1992).
- the compositions are prepared essentially by co-precipitation which results in the incorporation of lipid in the crystalline structure of the solvate. The residual solvent trapped in the solvate crystals is given as a possible reason for the improved solubility of the poorly water soluble compound.
- PCT/US86/00637 discloses the use of non-esterified fatty acids and monoglycerides together with minor amounts of a monoacyl lipid (lysophosphatidylcholine) to form lipid particles which show improved oral absorption for various lipophilic compounds. Improved oral absorption is claimed to be due to the unique properties of the mixture.
- WO 98/58629 describes lipid compositions comprising at least one monoacyl lipid, e.g. monoacyl phospholipid and mixtures of monoacyl and diacyl phospholipids that are effective in carrying lipophilic compounds in molecular form.
- the compositions may be a waxy solid, a paste-like material or a viscous fluid suitable for filling into hard or soft gelatin capsules.
- WO 00/38655 describes a dosage form comprising a plurality of particles having interior pores and a liquid, active agent formulation in the pores to retain substantially all of the liquid active agent formulations in the pores during compaction.
- the method explicitly requires the liquid to remain inside the pores dissolved in a non volatile liquid such as propylene glycol.
- the procedure used is for absorbing liquids described in the NeusilinTM brochure (Fuji Chemical).
- WO 00/38655 is concerned with powder compositions containing absorbed liquid solutions/ suspensions and a method to modify the dissolution characteristics of both hydrophilic and lipophilic compounds.
- US 20010009677 discloses a solid oral dosage form comprising a solid carrier of magnesium alumina silicate, an effective amount of a lipophilic stanol ester and a mixed micelle surfactant system to solubilise the compound using a hot melt method, which coats and deposit the compound on the external surfaces of the core particles. It is silent with respect to the lipophilic compound being sequestered and maintained in ultra fine form or in molecular solution inside the pores of the carrier. Furthermore, the compositions do not comprise membrane lipids or a method of introducing the compound into the pores of a support medium by means of a solvent with or without membrane lipid and/ or surfactants, followed by removal of the solvent.
- US-A-5,624,687 discloses a soluble salt of compounds with low water solubility at elevated pH dissolved in an organic solvent mixture containing an enteric base coated onto core particles like magnesium alumina silicate to make a solid quick-dissolution preparation with increased oral bioavailability. It is claimed that the compound is deposited as a solid solution in an enteric base on the exterior surfaces of the core particles from sprayed droplets.
- the core particles include calcium hydrogen phosphate, sucrose, lactose, starch and crystalline cellulose. It does not disclose the sequestration of drugs which have low water solubility at neutral pH in the internal pores of a porous support medium in ultra fine or molecular form with or without membrane lipids and/ or surfactants.
- the solid dispersion carrier is a surfactant which solubilises the drug without using a solvent and the increase in dissolution was attributed to the formation of a solid solution on the surface of the particles.
- the method does not involve a solvent to reach the internal pores of the carrier, from where it is removed.
- Subject matter of the present invention is a composition, particularly a pharmaceutical or cosmetic composition, for improving the dispersibility of biologically active compounds having low water solubility regardless of pH which comprises, a) A biologically effective amount of at least one biologically active compound having low water solubility; b) A porous particulate support material capable of incorporating within its pores the biologically active compound; c) A membrane lipid; or, in the alternative, a membrane lipid combined with a pharmaceutically acceptable surfactant; and, optionally, d) Additional pharmaceutically acceptable excipients.
- “Compounds” are biologically active substances that have a physiological and/ or pharmacological effect. They are also referred to as drugs or therapeutic agents and include nutrition agents, food and feed additives, cosmetic and diagnostic substances. "Low water solubility” means any compound that requires more than 10 parts of water to dissolve 1 part of the compound. It spans the definitions between sparingly soluble (from 10 to 30) to very slightly soluble (from 1000 to 10 000) and practically insoluble or insoluble (10 000 and over) as defined in USP 24. The term includes hydrophobic or lipophilic or amphipathic compounds. “Lipid” refers to membrane lipids, which include phospholipids, glycolipids, ceramides, gangliosides and cerebrosides. The term as used herein refers to a single type as well as to mixtures thereof.
- Lipid suspension refers to an aqueous dispersion of lipid particles.
- Silicone material refers to highly porous clusters or agglomerates of small particles held together by physical forces creating large internal surfaces in the inter-particulate pores or channels which are accessible to solvents.
- Ultra fine form implies that the compound is in the finest state of subdivision possibly as amorphous particles or ultrathin layer but not in molecular dispersion or solution in the pores, or after hydration and contact of the composition with aqueous media.
- Adsorption refers to the containment or sequestering of a compound on the external as well as internal surfaces lining the pores of the support material.
- “adsorption” refers to the containment, impregnation or sequestering of a compound “essentially” (more than 90%, particularly 95%) on the external as well as internal surfaces lining the pores of the support material.
- "Ultrafine dispersion” is achieved if more than 50% of the drug is able to pass a 0.45 micron filter after incubation of the composition in a suitable dissolution medium, such as 0.5% SDS (sodium dodecyl sulphate) in 0.1N HC1 or another dissolution media used for dissolution testing.
- composition according to the present invention has improved dispersibility and dissolution profiles and may be used as such, or preferably converted to free flowing powders or granules with excipients such as sugars and polymers which increase the bulk density.
- the composition may also be processed further by known methods, such as extrusion, and compacted into tablets or filled into hard gelatine capsules or the like by addition of suitable additional excipients commonly used in solid dosage forms.
- Organic and inorganic materials widely used as anti-caking agents, disintegrants, fillers, adsorbents, pulverising or moulding excipients may be used.
- the composition may be suspended in a liquid vehicle for topical applications.
- the support material dissolves at least partially in the low pH conditions of the upper Gl-tract to release the compound in ultra fine form or in molecular dispersion.
- the key function of the support material is to enable a compound with low water solubility to be deposited inside the pores in highly dispersive ultrafine form.
- the prior art only describes the use of solid particulate carriers either to absorb liquids to facilitate handling and storage or as diluents and core materials coated on the external surfaces of the particles by a solid compound.
- dissolution takes place inside the body after oral ad- ministration. It is believed that the support material impregnated with lipophilic substance with or without surfactant and/ or lipid readily disperses and/ or dissolves in the GI- tract, releasing the lipophilic compound from the pores. This improves the dissolution profile of a compound with low water solubility.
- a powder composition comprising the compound sequestered in ultra fine form inside a support material may be further treated with acid medium in a suitable container.
- the support material is dissolved and the lipophilic compound may be harvested or collected as ultra fine powder.
- the powder has improved dispersibility and dissolution profiles and may be processed further into suitable dosage forms.
- An alternative and preferred embodiment of the invention relates to a pharmaceutical or cosmetic composition for improving the dispersibility of biologically active compounds having low water solubility, which comprises a) A therapeutically or cosmetically effective amount of at least one biologically active compound having low water solubility; b) A porous particulate support material capable of incorporating within its pores the biologically active compound; c) At least one membrane lipid; and, optionally, d) Additional pharmaceutically acceptable excipients.
- Another alternative embodiment of the invention relates to a pharmaceutical or cosmetic composition for improving the dispersibility of biologically active compounds having low water solubility, which comprises a) A therapeutically or cosmetically effective amount of at least one biologically active compound having low water solubility; b) A porous particulate support material capable of incorporating within its pores the biologically active compound; c) At least one membrane lipid combined with at least one pharmaceutically acceptable surfactant; and, optionally, d) Additional pharmaceutically acceptable excipients.
- An example of the invention relates to a pharmaceutical composition for improving the dispersibility of a HIV-protease inhibitor, particularly a HIV-1-protease inhibitor of low water solubility, which comprises a) A therapeutically effective amount of a HIV protease inhibitor; b) A porous particulate support material capable of incorporating within its pores the biologically active compound, and optionally; c) At least one membrane lipid and/ or at least one a pharmaceutically acceptable surfactant; and, optionally, d) Additional pharmaceutically acceptable excipients.
- Another selective and preferred embodiment of the invention relates to a pharmaceutical composition for improving the dispersibility of cyclosporins, particularly cyclosporin A or G, which comprises a) A therapeutically effective amount of cyclosporin A; b) A porous particulate support material capable of incorporating within its pores the biologically active compound; and, optionally; c) A pharmaceutically acceptable surfactant; or, in the alternative, a pharmaceutically acceptable surfactant combined with a membrane lipid; and, optionally, d) Additional pharmaceutically acceptable excipients.
- a further embodiment of the invention relates to a pharmaceutical composition for improving the dispersibility of peripheral benzodiazepine receptor ligand with activity in neuro-degenerative diseases which comprises: . . J . .
- compositions comprising a porous support material and organic solutions/ aqueous suspensions containing a drug and a surfactant and/ or a membrane lipid as a minor component(s) as compared to the amount of the support material, and which yields after hydration and/ or dissolution of the carrier (dosage form) in-vivo or in-vitro, ultra fine drug particles associated with surfactant or a mixture of surfactant and lipids, possibly in the amorphous state; or
- the invention relates to a process for the preparation of a pharmaceutical or cosmetic dosage form, as defined above, which is characterised in that in a suitable solvent or solvent mixture a homogeneous dispersion is prepared, which comprises, a) A biologically effective amount of at least one biologically active compound having low water solubility; b) A porous particulate support material capable of incorporating within its pores the biologically active compound; and, optionally, c) A membrane phospholipid; and/ or a pharmaceutically acceptable surfactant; d) Additional pharmaceutically acceptable excipients.
- Component d) may be added during loading and impregnation of the compound with low water solubility using a solvent or solvent mixture, followed by drying or solvent removal. Component d) may be added during or after loading and impregnation of the compound. The homogeneous dispersion is converted to a dosage form suitable for pharmaceutical or cosmetic administration.
- the process comprises the following inventive process embodiments, wherein the component a), biologically active compound having low water solubility is present in combination with the component b), the porous particulate support material, the presence of components a) and b) combined with
- a membrane lipid as defined below, or
- a pharmaceutically or cosmetically acceptable surfactant as defined above; is optional.
- the presence of additional pharmaceutically or cosmetically acceptable excipients, component d), is optional in any of the embodiments described above.
- a further embodiment of the invention relates to a method for improving the dispersibility of biologically active compounds having low water solubility, which comprises i) Dissolving or dispersing a biologically effective amount of at least one biologically active compound having low water solubility in a suitable volatile pharmaceutically acceptable solvent; ii) Dissolving or dispersing in the compound solution at least one membrane phospholipid; or, in the alternative, at least one pharmaceutically acceptable surfactant; or mixture of said membrane lipid and surfactant, optionally, additional pharmaceutically acceptable excipients; and iii) Adding the solution to a porous particulate support material capable of incorporating within its pores the biologically active compound; followed by removal of the solvent, to produce a composition with increased aqueous dispersibility of said compound.
- An alternative method relates to a method for improving the dispersibility of biologically active compounds having low water solubility, which comprises j) Dissolving or dispersing a biologically effective amount of at least one biologically active compound having low water solubility in a suitable volatile pharmaceutically acceptable solvent; ii) Adding the solution or dispersion to a porous particulate support material capable of incorporating within its pores the biologically active compound; followed by removal of the solvent, to produce a composition with increased aqueous dispersibility of said compound and optionally other excipients.
- Another embodiment of the invention relates to a specific method for preparing said dosage forms, which includes the following process steps: i) dissolving or dispersing drug in a solvent or solvent water mixture or aqueous medium containing, optionally at least one membrane lipid and/ or pharmaceutically acceptable surfactant. ii) adding the suspension or solution to a porous support material; iii) optionally followed by removal of said water or solvent.
- the present invention relates particularly to processes and methods for providing:
- a composition for improving the dispersibility, dissolution and the bioavailability of a biologically active compound having low water solubility comprising, a) A therapeutic amount of a biologically active compound having low water solubility; b) A particulate porous support material capable of sequestering the biologically active compound within its pores; c) At least one membrane lipid or a mixture of membrane lipid and surfactant and, optionally, d) Other pharmaceutically acceptable excipients.
- composition for improving the dispersibility, dissolution and the bioavailability of a biologically active compound having low water solubility comprising, a) A therapeutic amount of a biologically active compound having low water solubility; b) A particulate porous support material capable of sequestering the biologically active compound within its pores; optionally c) At least one membrane lipid and/ or a mixture of membrane lipid and surfactant ; d) Other pharmaceutically acceptable excipients.
- a composition for improving the dispersibility, dissolution and the bioavailability of a biologically active compound having low water solubility comprising, a) A therapeutic amount of a biologically active compound having low water solubility; b) A particulate porous support material capable of sequestering the biologically active compound within its pores; c) At least one surfactant, and optionally at least one membrane lipid and, optionally, d) Other pharmaceutically acceptable excipients.
- compositions, in which the surf actant is selected from the group consisting of d- ⁇ -tocopheryl polyethylene glycol 1000 succinate, a poloxamer, polyethoxylated castor oil derivative and a protective colloid
- compositions wherein the weight ratio of the surfactant to active compound with low water solubility, or preferably, surfactant or surfactant lipid mixture to support material is less or equal to 1 : 2 by weight
- a dosage form for administration of a biologically active compound having low water solubility which is derived from further processing a composition as mentioned before and comprising a therapeutic amount of a biologically active compound having low water solubility • A dosage form for administration of a biologically active compound having low water solubility which is derived from further processing a composition as mentioned before and comprising a therapeutic amount of a biologically active compound having low water solubility and in which the support material is amorphous aluminometasilicate or calcium silicate in particulate form • A dosage form for administration of a biologically active compound having low water solubility which is derived from further processing a composition as mentioned before comprising a therapeutic amount of a biologically active compound having low water solubility; and in which the support material is amorphous Al 2 O 3 -MgO-1.7 SiO-7H 2 O or Ca 2 SiO 4 or CasSiOs or a mixture of Ca 2 SiO 4 and Ca 3 SiOs in particulate form
- a dosage form for administration of a biologically active compound having low water solubility which is derived from further processing a composition as mentioned before comprising a therapeutic amount of a biologically active compound having low water solubility and in which the support material is dibasic anhydrous calcium phosphate
- a dosage form for administration of a biologically active compound having low water solubility which is derived from further processing a composition as mentioned before comprising a therapeutic amount of a biologically active compound having low water solubility, which after (partial) dissolution of the porous support in 0.1 M HCL containing 0.5% sodium dodecylsulphate results in a molecular association or solution of the biologically active compound having low water solubility in the membrane lipid
- a method for the preparation of a composition for improving the dissolution and the bioavailability of a biologically active compound having low water solubility wherein, A biologically active compound having low water solubility and surfactant and optionally a lipid are first finely dispersed or preferably dissolved in a suitable solvent,
- the solution or suspension is mixed with a porous support material, followed by drying or solvent removal preferably by means of reduced pressure or vacuum to ensure maximum adsorption and sequestering of the compound in the pores; optionally the support material is dissolved, yielding a solution or an ultra fine suspension of the compound, preferably in association with the lipid; optionally the solution of ultra fine suspension is further processed to obtain a free flowing powder by evaporating the solvent •
- a method for the preparation of a composition for improving the dissolution and the bioavailability of a biologically active compound having low water solubility wherein,
- a biologically active compound having low water solubility and optionally surfactant and/ or a lipid is first finely dispersed or preferably dissolved in a suitable solvent,
- the solution or suspension is mixed with a porous support material, followed by drying or solvent removal preferably by means of reduced pressure or vacuum to ensure maximum adsorption and sequestering of the compound in the pores; optionally the support material is dissolved, yielding a solution or an ultra fine suspension of the compound, preferably in association with the lipid; optionally the solution of ultra fine suspension is further processed to obtain a free flowing powder by evaporating the solvent
- a therapeutic amount of a biologically active compound having low water solubility and surfactant and optionally a lipid are first finely dispersed or preferably dissolved in a suitable solvent;
- the solution or dispersion is loaded into the pores of a porous support material, preferably by means of reduced pressure or vacuum to ensure maximum adsorption and sequestering of the compound in the pores;
- the support material is dissolved, yielding a solution or an ultra fine suspension of the compound, preferably in association with the lipid;
- composition is further processed by extrusion into granules e.g. for filling in hard gelatine capsules, and/ or compacted into tablets by addition of suitable excipients commonly used in solid dosage forms, such as, for example as anti-caking agents, disintegrants, fillers, adsorptives, pulverizing and moulding excipients.
- suitable excipients commonly used in solid dosage forms, such as, for example as anti-caking agents, disintegrants, fillers, adsorptives, pulverizing and moulding excipients.
- a biologically active compound having low water solubility is, in particular, any therapeutic agent or a combination of different therapeutic agents of low water solubility, which is suitable in a therapeutically effective amount for the intended mode of administration, e.g. topi- cal, parenteral, e.g. intramuscular in the form of injection dispersions, or oral, e.g. in the form of capsule fillings.
- a preferred therapeutic agent is sparingly soluble in water and has a solubility in water of less than 500 mg/1000 ml, especially of less than 100 mg/1000 ml.
- Suitable for topical, parenteral, e.g. intramuscular, or oral administration, e.g. as capsule fillings are sparingly soluble therapeutic agents, e.g.
- immunosuppressants having a macrolide structure, typically cyclosporin A, cyclosporin G, rapamycin, tacrolimus, deoxyspergualin, mycophenolate-mofetil, gusperimus, non-steroidal antiphlogistic agents and salts thereof, typically acetylsalicylic acid, ibuprofen or S(+)-ibuprofen, indomethacin, diclofenac (Na and K-salt), piroxicam, meloxicam, tenoxicam, naproxen, ketoprofen, flurbiprofen, fenoprofen, felbinac, sulindac, etodolac, oxyphenbutazone, phenylbutazone, nabumetone; dihydro- pyridine derivatives having cardiovascular activity, e.g.
- the above-mentioned therapeutic agent may be present in the pharmaceutical composition in the form of a pharmaceutically acceptable salt, typically as hydrobromide, hydrochloride, mesylate, acetate, succinate, lac- tate, tartrate, fumarate, sulphate, maleate, and the like.
- a pharmaceutically acceptable salt typically as hydrobromide, hydrochloride, mesylate, acetate, succinate, lac- tate, tartrate, fumarate, sulphate, maleate, and the like.
- corticoids for dermal administration e.g. halogenated corticoids, e.g.
- corticoids e
- corticoids may also be combined with antimycotic, sulphonamides or estrogen derivatives.
- Suitable for dermal formulations are also astringents, anti-acne agents, antipsoriasis agents, or antipruritic agents.
- Particularly suitable for topical administration are topical antibiotics, e.g.
- tetracyclin erythromycin, fusidinic acid, framycetine sulphate, neomycin, meclocyclin, gentamycin, leu- comycin, streptomycin, ganefromycin, rifamexil, ramoplanin, spiramycin, clindamycin, ba- citracin, oxytetracyclin, sulphonamides, and other antibacterial and antiviral agents, e.g. po- dophyllotoxin, idoxuridin, heparine, foscarnet, vidarabine, tromantadine, idoxuridine, aci- clovir, antimycotic agents, e.g.
- antibiotics and antimycotic agents may be combined with other corti- costeroids, antibiotics or antimycotic agents.
- sunscreens for topical administration are active agents such as UV-B filtering substances, e.g. 4-aminobenzoic acid, homosalate, oxybenzon, 3-imidazolyl-4-yl-acrylic acid and derivatives thereof, 2-phenylbenzimidazol-5-sulphonic acid and salts thereof; 2,3- dihydroxypropyl-4-amino-benzoate, 2-ethylhexyl-4-dimethyl-aminobenzoate, ethyl 4-[bis(2- hydroxypropyl)amino]benzoate, 2-ethylhexyl-4-methoxy-cinnamate, 2-ethylhexylsalicylate, ethylpoly(oxyethylene)-4- ⁇ bis-[(2-hydroxyethyl)-polyoxyethylene]amino ⁇ benzoate, 3-(4- imidazolyl) acrylic acid, isopentyl 4-methoxycinnamate, 4-isopropylbenzoic
- Particularly suitable for topical administration are also lipophilic vitamins, typically vitamin A (retinol, free acid or derivatives thereof), B (Bl: thiamine, B2: riboflavine, B6: pyrid- oxin, panthenol, pantothenic acid, vitamin B12 and combinations thereof), vitamin C, D, E (tocopherol), biotin or vitamin K; membrane hpids with functional properties, also retinoids and carotinoids, oils with therapeutic, antimicrobial, cosmetic organoleptic properties, such as cumin seed oil, wheat germ oil, shea butter, sebum regulators and sterols, pumpkin oil, borage and evening primrose oils.
- the concentration of the therapeutic agent or combination thereof is determined by the known dosage amount to be administered and can be in the range from 1.0 to 30.0% by weight, preferably from 5.0 to 20.0% by weight, more particularly from 5.0 to 12.0% by weight, based on the weight of the carrier composition.
- Suitable lipophilic feed additives are astaxanthin, canthaxanthin, zeaxanthin and lutein.
- compounds used in nutriceuticals are ubiquinones, sitostanols, sitosterols and antioxidants such as lycopenes, B-carotene, polyphenols, isoflavones.
- lipophilic drugs are immunosuppressants e.g. cyclosporin A, cytostatics e.g. taxol, anti inflammatories e.g. ibuprofen, HIV proteases, antinypertensives e.g. nifedipine, felodipine, photosensitisers e.g. benzoporphyrin, zinc phthalocyanine tin-ethyl purpurine and antibiotics e.g. amphotericin, ny statin, chloramphenicol.
- immunosuppressants e.g. cyclosporin A
- cytostatics e.g. taxol
- anti inflammatories e.g. ibuprofen
- HIV proteases HIV proteases
- antinypertensives e.g. nifedipine, felodipine
- photosensitisers e.g. benzoporphyrin
- the support material is selected such that it does not chemically react with the active compound and serves little physiological role other than to maintain and stabilise a hydrophobic compound in dispersion.
- the primary particles making up the agglomerates are smaller than 1 ⁇ and may be as small as about 0.02 ⁇ . These are held together by physical forces.
- the size of the agglomerates is in the range between about 2 ⁇ to about 250 ⁇ , with inter-particle channels or pores accounting for specific surface areas between 50m 2 / g to 500 m 2 /g. Because of the very large internal surfaces available for adsorption, the support material is porous and highly absorbent.
- the invention comprises as component b) a porous particulate support material selected from the group consisting of, for example, amorphous aluminometasilicate, calciumsilicate, silica, including porous silicon dioxide and silicic acid, dibasic anhydrous calcium phosphate and maltodextrin and polystyrene beads/ micro- sponges.
- a porous particulate support material selected from the group consisting of, for example, amorphous aluminometasilicate, calciumsilicate, silica, including porous silicon dioxide and silicic acid, dibasic anhydrous calcium phosphate and maltodextrin and polystyrene beads/ micro- sponges.
- Preferred support materials which are employed in this invention include inorganic solids, e.g. calcium hydrogen phosphate, which is corresponds to the general formula CaHP ⁇ 4*mH 2 O (m: 0 D m D2), particularly support materials commercially available of the type Fujicalin®, and magnesium aluminometasilicate, which corresponds to the general formula Al 2 O 3 , MgO , 2 Si0 2 , n H 2 O (n: 0 C3 n D2), particularly support materials commercially available of the type Neusilin®, calcium silicate, e.g. Ca2SiO4 or Ca3SiO, and dibasic anhydrous calcium phosphate.
- inorganic solids e.g. calcium hydrogen phosphate, which is corresponds to the general formula CaHP ⁇ 4*mH 2 O (m: 0 D m D2)
- support materials commercially available of the type Fujicalin®
- magnesium aluminometasilicate which corresponds to the general formula Al 2 O
- the composition comprises as component b) a porous particulate support material selected from the group consisting of amorphous Al 2 0 3 « MgO-2SiO 2 « nH 2 0, CaHPO 4 » mH 2 O, CaSiO 4 , CasSiOs and dibasic anhydrous calcium phosphate.
- Suitable FUJICALIN products are SG and S and characterised by a mean pore size of 7,0 x 10- 10 m, a mean particle size of about 2-10 ⁇ , a specific volume of about 1.5 ml/g or more, a BET specific surface area of 20 m 2 /g to 60 m 2 /g, and an oil and water absorption capacity of about 0.7 ml/g.
- Suitable NEUSILIN products are Grades SI, SGI, UFL2, US2, FH2, FLl, FL2,S2, SG2,NFL2N and NS2N. Particularly preferred grades are S , SGI US2 and UFL2. The most preferred support material for many applications is grade US2.
- Those materials which are amorphous, typically have a specific area of about 100 m 2 /g to about 300 m 2 /g, an oil absorption capacity of about 1.3 ml/g to about 3.4 ml/g, a mean particle size of about 1 ⁇ to about 2 ⁇ and a spe- cif ic volume of about 2.1 ml/ g to about 12 ml/ g.
- Suitable support materials are precipitated amorphous calcium silicate, e.g. Zeo- pharm® 600 with 300 m 2 /g, and oil absorption capacity of at least 450 ml/ 100 g, Hubersorb® 250 NF with oil absorbing capacity of 250 - 300 ml/ 100 g and Zeopharm® 80 (precipitated amorphous silica) with 140 m 2 /g and oil absorption capacity of 185 - 215 ml/ 100 g.
- amorphous calcium silicate e.g. Zeo- pharm® 600 with 300 m 2 /g, and oil absorption capacity of at least 450 ml/ 100 g
- Hubersorb® 250 NF with oil absorbing capacity of 250 - 300 ml/ 100 g
- Zeopharm® 80 precipitated amorphous silica
- amorphous support material typically have a specific area of about 100 m 2 /g to about 300 m 2 /g, an oil absorption capacity of about 1.3 ml/g to about 4.5 ml/g, a mean particle size of from about 1 ⁇ to about 2 - 14 ⁇ and a specific volume of about 2.1 ml/g to about 12 ml/g.
- Another organic support material is maltodextrin supplied by Matsutani Chemical industry Co., Ltd. Japan (PineflowTM PineflowTM S) which has a specific surface area of 0.36 m 2 /g. 0.44 m 2 / g and oils absorbable capacity of 120 and 160%, respectively.
- Alternative organic or inorganic porous materials may be used, as long as they have no deleterious effect on the active compound and present internal surface areas, which are comparably large.
- the amount of support material depends on the surface area required for sequestering a solution or dispersion of the hydrophobic compound inside the pores and the type of solution employed. Generally, if the surface area provided by the particle agglomerates is in the range of 100 m 2 /g to 500 m 2 /g, about 2 g to about 10 g of the support material may be needed for every ml of liquid. However this is only a general guide and the ratio of the two components depends very much on the properties of the compound and processing conditions.
- a suitable membrane lipid from synthetic or natural origin is selected from the group consisting of phospholipids, sphingolipids and glycolipids and mixtures thereof.
- Membrane lipids are components of living cells. Suitable membrane lipids are phospholipids, which are the most abundant membrane lipid occurring in nature. They can be uncharged, zwitterionic, negatively or positively charged. Examples of uncharged phospholipids are phosphatidyl choline, phosphatidyl ethanolamine or their mono acyl derivatives, sphingomyelin and cholesterol. Examples of negatively charged membrane lipids are phosphatidyl serrne, phosphatidyl glycerol, phosphatidic acid, phosphatidyl inositol, cerebrocides, glycolipids cardiolipin.
- the membrane lipids may be derived from natural plant or animal or microbiological sources, synthesised or partially synthesised, including polyethylene glycol (PEG) derived diacyl and monoacyl equivalents. Special fractions of soy lecithins which contain several phosholipid types, their monoacyl- derivatives, non polar lipids and free fatty acids have improved solubilisation potential and low viscosity due to their heterogeneous composition and may be preferred in some cases. Such blends are commercially available, for example, from Lipoid KG.
- the term membrane lipid of natural origin also comprises membrane Hpids that have been modified by enzymatic action from natural sources.
- the membrane phospholipid of component c) is selected from the group of diacylphosphatidylcholine, monoacylphosphatidylcholine and mixtures thereof.
- the membrane phospholipid of component c) selected from the group consisting of soybean lecithin, soybean lecithin with about 80%, preferably more than about 90%, monoacylphosphatidylcholine content and enzyme modified soy lipid with about 60%, preferably more than about 70%, monoacylphosphatidylcholine content.
- a suitable phospholipid of natural or synthetic origin is represented by the general formula
- Ri is C10-20acyl
- R 2 is hydrogen or C10-20acyl
- R3 is hydrogen, 2-trimethylamino-l- ethyl, 2-amino-l-ethyl, Cl-4alkyl, Cl-5alkyl substituted by carboxy, C2-5alkyl substituted by hydroxy, C2-5alkyl substituted by carboxy and hydroxy, C2-5-alkyl substituted by carboxy and amino, or an inositol group or a glyceryl group, or a salt of such a compound.
- Suitable sphingolipids and glycolipids of natural or synthetic origin are represented by the general formula 1 H — R.
- X represents the ethylene or vinylen group or a bivalent group of the partial formula:
- OH H H Ri is hydroxy, the phosphatidylcholine, the phosphatidylethanolamine group or hydroxy bound as ⁇ -glucoside to a mono- or oligosaccharide group or is an oligosaccharide group substituted by N-acetylneuraminic acid groups;
- R 2 is C16-30-acyl, C16-30- ⁇ -hydroxyacyl or C16-30- ⁇ -hydroxyacyl, which is optionally esterif ied by a linoleic acid group;
- the nomenclature used for the phospholipids (I) and (II) and the numbering of the carbon atoms (sn-nomenclature, stereospecific numbering) are in accordance with the recommendations made by the IUPAC-IUB Commission on Biochemical Nomenclature (CBN) in Eur. J. of Biochem. 79, 11-21 (1977) "Nomenclature of Lipids".
- Ri and R 2 defined as C10-20acyl are preferably straight-chain C10- 20alkanoyl having an even number of carbon atoms and straight-chain C10-20alkenoyl having from one to three double bonds and an even number of carbon atoms.
- Straight-chain C10-20alkanoyl Ri and R 2 having an even number of carbon atoms are, for example, n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl.
- Straight-chain C10-20alkenoyl Ri and R 2 having from one to three double bonds and an even number of carbon atoms are, for example, 6-cis-, 6-trans-, 9-cis- or 9-trans-dodecenoyl, -tetra- decenoyl, -hexadecenoyl, -octadecenoyl or -icosenoyl, especially 9-cis-octadecenoyl (oleoyl), and also 9,12-cis-octadecadienoyl or 9,12,15-cis-octadecatrienoyl.
- a phospholipid (1), wherein R 3 is 2-trimethylamino-l-ethyl, is referred to by the trivial name lecithin and a phospholipid (I), wherein R3 is 2-amino-l-ethyl, by the trivial name cephalin.
- Suitable are, for example, naturally occurring cephalin or lecithin, for example cephalin or lecithin from soybeans or chicken eggs having different or identical acyl groups Ri and R 2 , or mixtures thereof.
- the phospholipid (I) may also be of synthetic origin.
- synthetic phospholipid is used to define phospholipids having a uniform composition in respect of Ri and R 2 .
- Such synthetic phospholipids are preferably the above-defined lecithins and cephalins, wherein the acyl groups Ri and R 2 have a defined structure and are derived from a defined fatty acid having a degree of purity greater than approximately 95%.
- Ri and R 2 may be identical or different and unsaturated or saturated.
- Ri is saturated, for example n-hexadecanoyl
- Naturally occurring defines (in definitions) a phospholipid (I) that does not have a uniform composition in respect of Ri and R 2 .
- Such natural phospholipids are likewise lecithins and cephalins, wherein the acyl groups Ri and R 2 are structurally undefinable and are derived from naturally occurring or enzymatically derived fatty acid mixtures.
- substantially pure defines (in definition) a phospholipid (I) having a degree of purity of more than 90% (by weight), preferably more than 95%, which can be demonstrated by means of suitable determination methods, for example by paper chromato- graphy, by thin-layer chromatography, by HPLC or by means of enzymatic colour testing.
- R 3 defined as Cl-C4alkyl is, for example, methyl or ethyl. Methyl is preferred.
- R 3 defined as Cl-5alkyl substituted by carboxy, C2-5alkyl substituted by hydroxy or C2- 5alkyl substituted by carboxy or hydroxy is, for example, 2-hydroxyethyl, 2,3-dihydroxy-n- propyl, carboxymethyl, 1- or 2-carboxyethyl, dicarboxymethyl, 2-carboxy-2-hydroxyethyl or 3-carboxy-2,3-dihydroxy-n-propyl.
- R3 defined as C2-5alkyl substituted by carboxy and amino is, for example, 3-amino-3- carboxy-n-propyl or 2-amino-2-carboxy-n-propyl, preferably 2-amino-2-carboxyethyl.
- a phospholipid (I) having those groups may be in salt form, for example in sodium or potassium salt form.
- Phospholipids (I) wherein R3 is the inositol or the glyceryl group are known by the names phosphatidylinositol and phosphatidylglycerol.
- the acyl radicals in the phospholipids (I) and in the other components are also customarily known by the names given in brackets:
- a salt of the phospholipid (I) is pharmaceutically acceptable. Salts are defined by the exis- tence of salt-forming groups in the substituent R 3 and by the free hydroxy group at the phosphorus atom. The formation of internal salts is also possible. Alkali metal salts, especially the sodium salt, are preferred.
- purified lecithin from soybeans for example of the LIPOID S 75 type
- Phospholipids (I) of natural or synthetic origin wherein Ri represents C10-20acyl, R 2 represents hydrogen and R3 is as defined above, are known under the term lysophospholipids, particularly lysolecithin, wherein Ri represents C10-20acyl, R 2 represents hydrogen and R3 represents is 2-trimethylamino-l-ethyl.
- sphingolipid or glycolipid of synthetic origin defines lipids (II), wherein segments of their molecular structure have been modified chemically, e.g. by hydration, transesterifica- tion, ester cleavage, esterification, substitution and other conventional process steps.
- synthetic lipid also defines lipids (II) which are obtainable by total synthesis.
- sphingolipid or glycolipid of natural origin defines lipids (II), which have only been submitted to purification processes, e.g. chromatographic separation methods, but have not been submitted to chemical modifications of their molecular structure.
- sphingolipid or glycolipid comprises lipids, which are defined by terms such as ceramides, sphingomyelines, cerebrosides, or gangliosides. Ceramides and sphingomyelines are classified together under the term sphingolipids, whereas cerebrosides and gangliosides are classified together under the term glycolipids.
- Ri is hydroxy.
- Known ceramides are classified as ceramide 1, 2, 3, 4, 5, 6 I and 6 II.
- the group of ceramides also comprises so-called synthetic questamides, e.g. questamide H, or so-called synthetic pseudo-ceramides, e.g. pseudo-ceramide SLE, and also lipids named ceramax.
- ceramides which primarily occur in human skin are defined according to INCI rules (formerly CTFA) as ceramides 3.
- 4-hydroxysphinganine phytosphin- gosin
- 4-sphingenine sphingosine
- Ri is the the phosphatidylcholine or the phosphatidylethanolamine group.
- R 2 representing C16-, C18- and C24-acyl is preferably n-hexadecanoyl (palmitoyl), n-octa- decanoyl (stearoyl), n-tetracosanoyl (lignocerinoyl), 9-cis-octadecenoyl (oleoyl) or 9-cis- or 12-cis-octadecadienoyl.
- R 2 representing C16-30-hydroxyacyl is preferably ⁇ -hydroxy-octadecanoyl or ⁇ -hydroxy- tetracosanoyl or a mixture thereof.
- acid amides in this position formed with C2-10- ⁇ -hydroxycarboxylic acids, e.g. hydroxyacetic acid (glycolic acid), 2- hydroxypropionic acid (lactic acid), 2-hydroxysuccinic acid (malic acid), ⁇ -hydroxy- phenylacetic acid (mandelic acid) or mixtures thereof.
- R 2 representing C16-30- ⁇ -hydroxyacyl, preferably in the sphingosine base phytosphingosine is, e.g. 23-octadecanoyloxytricosanoyl or 23-octadecanoyloxy-heptacosanoyl.
- glycolipid (II) of the cerebroside type Ri represents hydroxy bound as ⁇ -glucoside to a mono- or oligosaccharide group which is optionally substituted by N-acetyl.
- Representative monosaccharide groups are D-glucosyl and D-galactosyl, as well as N-acetyl- D-glucosamine and N-acetylgalactosamine.
- a glycolipid (II) of the ganglioside-type Ri represents hydroxy, which is also bound as ⁇ - glucoside to an oligosaccharide group containing at least three hexosyl groups, which may be substituted by at least one N-Acetylneuraminic acid groups. These lipids are classified as gangliosides.
- the compounds defined by the formula I are known and have been described in numerous textbooks and other references from biochemistry.
- membrane lipid as defined above is combined with a pharmaceutically acceptable surfactant. It is to be understood that membrane lipids are regarded and used as biologically active compounds in cosmetic and some applications.
- Suitable pharmaceutically acceptable surfactants include cationic, anionic or non-ionic surfactants.
- a suitable cationic surfactant is N-benzyl-N,N-dimethyl-N-2-[2-(4-(l,l,3,3-tetramethylbu- tyl)-phenoxy-ethoxy]-ethylammonio chloride, N-benzyl-N,N-dimethyl-N-2-[2-(3-methyl-4- (l,l,3,3-tetramethylbutyl)-phenoxy)-ethoxy]-ethylammonio chloride (methylbenzethonium chloride), n-dodecyltrimethylammonio chloride or bromide, trimethyl-n-tetradecylammonio chloride or bromide, n-hexadecyltrimethylammonio chloride or bromide (cetyltrimethylam- monium chloride or bromide), trimethyl-n-octa
- Ra represents a saturated or an unsaturated C6-C24hydrocarbon group
- A represents C2-C8alkylene
- m represents zero or one
- B represents the sulphonate or sulphate group
- Z+ represents a monovalent cation.
- Preferred anionic surfactants are sodium or potassium C12-C20alkylsulphate, e.g. sodium or potassium-n-dodecyl, -tetradecyl, -hexadecyl or octadecylsulphate or -sulphonate, or sodium or potassium C12-C20alkylethersulphate, e.g.
- Suitable non-ionic surfactants are selected from the group consisting of polyglycerol esters, polysorbates, mono- and diglycerides of fatty acids, propylene glycol esters, sucrose fatty acid esters and polyoxyethylene derivatives of sorbitan fatty acid esters. These surfactants are well known in the art and are commercially available.
- Suitable polyglycerol esters consist of substantially pure polyglycerol fatty acid ester or of a mixture of different polyglycerol fatty acid esters, wherein the polyglycerol chain preferably contains up to and including 10 units of glycerol, which are esterified with 1-10 acid radicals of saturated or unsaturated carboxylic acids having an even number of 8-20 carbon atoms.
- Suitable polyglycerol fatty acid esters having a uniformly defined structure are typically di- glycerol monocaprate, diglyceryl monolaurate, diglycerol diisostearate, diglycerol monoi- sostearate, diglycerol tetrastearate (polyglyceryl 2-tetrastearate), triglycerol monooleate (po- lyglyceryl 3-monooleate), triglycerol monolaurate, triglycerol mono stearate (polyglyceryl 3- stearate), triglycerol monoisosterate, hexaglycerol dioleate (polyglycerol 6-dioleate), hexaglycerol distearate (polyglycerol 6-distearate), decaglycerol dioleate (polyglycerol 10- dioleate), decaglycerol tetraoleate (polyg
- CTFA nomenclature is given within the brackets. These products are commercially available under the registered trade mark Caprol® (trade mark of Karlshamns USA Inc., Columbus Ohio). Specific product names: CAPROL 2G4S, 3GO, 3GS, 6G20, 6G2S, 10G2O, 10G4O, 10G100, 10G10S. Further products are available under the names of DGLC-MC, DGLC-ML, DGLC-DISOS, DGLC-MISOS, TGLC-ML and TGLC-MISOS from Solvay Alkali GmbH, D- 3002 Hannover.
- the mixture of different polyglycerol fatty acid esters is specified under names such as decaglycerol monooleate, dioleate, polyglycerol ester of mixed fatty acids, polyglycerol ester of the fatty acids, polyglycerol caprate, cocoate, laurate, lanolinate, isostearate or rizinolate and are commercially available under the registered trade mark Triodan® and Homo- dan®(trade mark of Grindsted Products, Grindsted Denmark), specific product names: TRIODAN 20, 55, R90 and HOMODAN MO; Radiamuls® (trade mark of Petrofina (FINA), Brussels Belgium), specific product name: RADIAMULS Poly 2253; under the name CAPROLPGE860 or ET, or under the registered trade mark Plurol®(trade mark of Gattefosse Etablmaschines, Saint-Priest, France), specific product name: PLUROL Stearique WL1009 or PLUROL Oleique WL1173.
- Applicable are especially the product specifications published by the indicated producers on the data sheets of the specified product, in particular specifications such as mono- ester content, drop point, free glycerol, free fatty acid, iodine value, form, antioxidants, HLB value, properties and stability.
- the cited polyglycerol fatty acid esters in particular conform to the requirements of number E475 of the EC food additives directive (EC directive 74/329) as well as the regulation of U.S. FDA Code 21 CFR_172.854.
- suitable polyglycerol esters include triglyceryl monostearate, hexaglyceryl distearate, hexaglyceryl monopalimate, hexaglyceryl dipalmitate, decaglyceryl distearate, decaglyceryl monoleate, decaglyceryl dioleate, decaglycerol monopalmitate, decaglycerol dipalmitate, decaglyceryl monostearate, oc- taglycerol monoleate, octaglycerol monostearate and decaglycerol monocaprylate.
- Suitable polysorbates include sorbitan fatty acid esters or polyoxyethylene sorbitan fatty acid esters.
- Sorbitan fatty acid esters preferably consists of a sorbitan fatty acid ester which is substantially pure, or of a mixture of different sorbitan fatty acid esters, and the sorbitan skeleton is esterified with 1-3 acid radicals of a saturated or unsaturated straight-chain carboxylic acid having an even number of 8-20 carbon atoms.
- the acid radical of a saturated carboxyHc acid having an even number of 8-20 carbon atoms which esterifies the sorbitan skeleton is preferably straight-chain with 12, 14, 16 and 18 carbon atoms, typically n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl.
- the acid radical of an unsaturated carboxylic acid having an even number of 8-20 carbon atoms is preferably straight-chain with 12, 14, 16 and 18 carbon atoms, typically oleoyl.
- Suitable sorbitan fatty acid esters are preferably sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan sesquioleate and sorbitan trioleate.
- the above-mentioned partial fatty acid ester of polyoxyethylene sorbitan consists preferably of a substantiaUy pure ester of sorbitan or a mixture of different esters of sorbitan in which the structure of the fatty acid groups and the length of the polyoxyethylene chains may vary.
- the hydrophiHc sorbitan is preferably etherified by three hydrophilic polyoxyethylene chains and esterified by a hydrophobic fatty acid group.
- the sorbitan may, however, alternatively be etherified by only one or two polyoxyethylene chains and correspondingly esterified by two or three fatty acid groups.
- the basic sorbitan structure is altogether substituted by a minimum of two and a maximum of three hydrophiHc groups, the term "hydrophiHc group" embracing the polyoxyethylene chains, whereas the fatty acid groups are hydrophobic.
- the polyoxyethylene chain is linear and has preferably from 4 to 10, especiaUy from 4 to 8, ethylene oxide units.
- the ester groups on the basic sorbitan structure are derived from a saturated or unsaturated, straight-chain carboxyHc acid having an even number of from 8 to 20 carbon atoms.
- the ester group derived from that carboxyHc acid is preferably straight- chained having 12, 14, 16 or 18 carbon atoms, for example n-dodecanoyl, n-tetradecanoyl, n- hexadecanoyl or n-octadecanoyl.
- the ester group derived from an unsaturated carboxylic acid having an even number of from 8 to 20 carbon atoms is preferably straight-chained having 12, 14, 16 or 18 carbon atoms, for example oleoyl.
- the mentioned esters of sorbitan are in conformity with the data given in the British Pharmacopoeia (speciaHsed monograph) or Ph.Helv.VII.
- the product specifications pubHshed by the mentioned manufacturers with the information on data sheets for the relevant product especiaUy specifications such as shape, colour, HLB value, viscosity, ascending melting point and solubiHty, apply.
- Suitable partial fatty acid esters of polyoxyethylene sorbitan are commercially obtainable under the trademark Tween® of ICI Corp. and known by the chemical names polyoxyethyl- ene(20 or 4)sorbitan monolaurate (TWEEN 20 and 21), polyoxyethylene(20)sorbitan mono- palrr ⁇ tate or monostearate (TWEEN 40 and 60), polyoxyethylene(4 or 20)sorbitan mono- stearate or tristearate (TWEEN 61 and 65), polyoxyethylene (20 or 5)sorbitan monooleate (TWEEN 80 or 81) and polyoxyethylene(20)sorbitan trioleate (TWEEN 85).
- sorbitan fatty acid esters and the polyglycerol fatty acid esters conform to the specifications Hsted in the British Pharmacopeia (special monography) or in Ph. Helv. VI. Applicable are especially the product specifications pubHshed by the indicated producers on the data sheets of the specified product, in particular specifications regarding e.g. form, colour, HLB value, viscosity, ascending melting point and solubiHty.
- suitable polysorbates are obtainable from the reaction product of monoglycerides or sorbitan esters with ethylene oxides.
- useful polysorbates include polyoxyethylene 20 mono- and diglycerides of saturated fatty acids, polyoxyethylene 4 sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene 20 sorbitan monooleate, polyoxyethylene 5 sorbitan monooleate, polyoxyethylene 20, sorbitan trioleate, sorbitan monopal itate, sorbitan monolaurate, propylene glycol monolaurate, glycerol monostearate, diglycerol monostearate, glycerol lac- tyl-palmitate.
- Another group of suitable surfactants includes, with HLB values provided in brackets, includes decaglycerol monolaurate [15.5]; decaglycerol distearate [10.5]; decaglycerol dioleate [10.5]; decaglycerol dipalmitate [11.0]; decaglycerol monostearate [13.0]; decaglycerol monooleate [13.5]; hexaglycerol monostearate [12.0]; hexaglycerol monooleate [10.5]; hexaglycerol mono-shortening [12.0]; polyoxyethylene (20) sorbitan monolaurate [16.7]; polyoxyethylene (4) sorbitan monolaurate [13.3]; polyoxyethylene (20) sorbitan monopalmi- tate [15.6]; polyoxyethylene (20) sorbitan monostearate [14.9]; polyoxyethylene (20) sorbitan tristearate [10.5]
- the HLB value for a surfactant is an expression of its hydrophiHc-HpophiHc balance, i.e., the balance of the size and strength of the hydrophiHc (polar) and HpophiHc (non-polar) groups of the surfactant.
- Lactic acid derivatives include sodium stearoyl lactylate and calcium stearoyl lactylate.
- a particularly preferred surfactant is d-Alpha tocopheryl polyethylene glycol 1000 succinate (TPGS)
- surfactants or substances with amphipathic character like poloxamers polyethoxylated castor oil derivatives and protective coUoids like low- and high-molecular-weight components of, for example, gelatin, fish gelatin, starch, dextrin, plant proteins, pectin, gum arabic, casein, caseinate or mixtures of these, the protein-containing protective colloids, in particular non-gelling low-molecular-weight protein hydrolysates and higher-molecular- weight gelling gelatins being preferred.
- poly(vinylalcohol), polyvinylpyrroHdone, methyl cellulose, carboxymethyl ceUulose, hydroxypropyl ceUulose and alginates can also be used.
- the surfactants suitable for the invention are not limited to the examples provided above. In general, the weight ratio of surfactant to support material is less or equal to 1 : 2, regardless of drug content. Where TPGS is employed as the preferred surfactant, it may be present in excess of the active compound.
- Suitable pharmaceuticaUy acceptable additional excipients are added to the carrier composition in such an amount as to make up 100% by weight together with the amounts of components a), b) and c) as weU as of the therapeutic agent or combination thereof. Additional excipients can be present in the composition in amounts of 0% to c.75% by weight. Additional excipients depend on the choice of the pharmaceutical dosage form.
- PharmaceuticaHy acceptable diluents are added to Hquid dosage forms, such as drops, suspensions or capsule fillings, typicaUy ethanol, propanol, isopropanol, propylene glycol, polyethylene glycol, butylenes glycol , hexalene glycol, or mixture thereof, glycerol or water, or mixtures thereof.
- a suitable pharmaceutical diluent is a carrier Hquid, e.g. water, which is optionaHy admixed with a C2-C4-alkanol, especiaUy ethanol, and is present in the composition in the degree of purity necessary for the intended pharmaceutical or cosmetic administration.
- Hquid e.g. water
- a carrier Hquid e.g. water
- the carrier Hquid ethanol is optionaUy admixed as C2-C4-alkanol when parenteral dosage forms are intended. In that event ethanol is present, ethanol has the degree of purity (at least 96%) prescribed for injection formulations. The proportion of ethanol for injection formulations may vary within wide limits from about 1.0% to about 10.0%. For topical dosage forms or cosmetic uses, ethanol, isopropanol or mixtures thereof may be optionaUy admixed as C2- C4-alkanol. The proportion of C2-C4-alkanol for topical formulations or cosmetic uses may vary within wide limits from about 0.1% to about 10.0%, preferably 0.1% to 2.0%. Other suitable excipients are hydrophiHc and HpophiHc polymers which are used as fiUers bulking agents and viscosity improvers. Examples are the natural gums, ceUulose derivatives etc.
- Typical additives may be present in the composition, which are characteristic for the intended pharmaceutical dosage form or cosmetic uses. They have a degree of purity in ac- cordance with the regulations of the national pharmacopoeias mentioned above. Depending on the intended use, additives may be water soluble or Hpid soluble. Suitable additives /excipients include those that are useful for the preparation of o/w, w/o, w/o/w emulsions, gels, ointments, creams, oUs, lotions, foams, or sprays. The addition of preserving agents, antioxidants, stabilizers or softening agents is recommended.
- a preferred additive in topical pharmaceutical and cosmetic compositions is cholesterol or a corresponding salt thereof, e.g. cholesterol sulphate with the purity necessary for the intended cosmetic or pharmaceutical administration.
- Suitable additives for pharmaceutical and particularly cosmetic compositions are also free fatty acids derived by conventional ester cleavage from the above-mentioned triglyc- erides (III), surfactants, e.g. anionic, cationic, or amphoteric, gel-forming agents, emulsifiers, e.g. ethoxylated fatty alcohols, hydrogenated ethoxylated castor oUs, partial esters of fatty acids and modified fatty acids with glycerol, polyglycerol, and sorbitol, orthophosphoric acid esters, or siHcone surfactants, HpophiHc constituents, e.g.
- surfactants e.g. anionic, cationic, or amphoteric
- gel-forming agents emulsifiers, e.g. ethoxylated fatty alcohols, hydrogenated ethoxylated castor oUs, partial esters of fatty acids and modified fatty acids with
- soHd, semisolid, and Hquid hydrocarbons natural oUs and waxes, suicone and volatile siHcone oU, guerbet alcohols, fatty acid esters, isostearic acid derivatives, co-emulsifiers, thickeners, gelling agents, foam stabiHzers, fat-restoring substances, pearl-lustre and turbidity agents, preservatives, dyes, colored pigments, perfume oUs, and preferably Ught filters (sunscreens).
- excipients can also be added to oral dosage form, e.g. capsule fillings, e.g. semi-synthetic or synthetic, substantiaUy pure triglyceride or a pharmaceuticaUy acceptable triglyceride of natural origin.
- a triglyceride of natural origin is preferred, for example groundnut, sesame, sunflower, oHve, maize kernel, soybean, castor, cottonseed, rape, thistle, grapeseed, fish or coconut oU.
- additives include for example preservatives, typicaUy benzyl alcohol, ethanol, p-hydroxybenzoate, sorbic acid; antioxidants, typically tocopherols, butylhydroxyanisol, butylhydroxytoluene, ascorbic acid, ascorbylpalmitate; stabUisers, typi- cally citric acid, tartaric acid, EDTA, flavourings or fragrances.
- Gelatin capsules and the like are suitably fiUed with conventional plasticisers to stabiHse the gelatin sheU.
- excipients are typically sorbitol, sorbitan, polyvinylpyrrolidone, hydroxy propylmethyl cellulose (HPMC), hydroxypropyl ceUulose, methyl ceUulose or colloidal siHcon dioxide.
- HPMC hydroxy propylmethyl cellulose
- a further object of the invention is to prepare a composition comprising a HpophiHc biologi- caUy active compound with low water solubiHty in molecular association or dispersion in at least one membrane Hpid sequestered in the interior of a porous support material without using organic solvents.
- HpophiHc compound This is done by partitioning a HpophiHc compound into an aqueous lipid suspension preferably using a high shear mixer.
- the compound is intercalated in the HpopMHc domain of the Hpid aggregates which is then loaded into the support material, foUowed by removal of excess water.
- the compound remains in molecular association with the Hpid and is sequestered in the pores of the support material.
- the Hpids used in this case are a mixture of a monoacyl Hpid and diacyl Hpid form natural soy or egg Hpids.
- the HpophiHc compound is first finely dispersed or preferably dissolved in a suitable solvent or solvent mixture , which may include a membrane Hpid and/ or surfactant.
- a suitable solvent or solvent mixture which may include a membrane Hpid and/ or surfactant.
- the solution or lipid suspension is loaded into the pores of the support material, preferably by means of reduced pressure or vacuum to ensure maximum adsorption on the internal surfaces lining the pores after solvent removal. Adequate deposition into the interior spaces of the particle agglomerates may also be obtained by e.g. spray drying and fluidised bed drying.
- the role of the solvent/ s is to dissolve the compound with low water solubiHty and carry it into the pores of the support material.
- the solvent/ solvent mixture employed is a volatile solvent with low viscosity.
- a surfactant is also included to reduce surface tension effects, de-aerate the surfaces of the material and aUow maximum penetration into the pores.
- the method employed enables the compound to be carried into the internal pores of the agglomerates either in solution or in ultra fine form when the solvent is removed. In contrast, solutions and suspensions in viscous Hquids including those using hot melt techniques are less efficient.
- the composition yields a highly dispersive solution or an ultra fine suspension of the drug, optionaUy in association with a Hpid/ surfactant, after release from or dissolution of the support material, compared to drug particles on their own.
- This is Ulustrated in the release profiles shown in Fig 1.
- the agglomerates have an internal surface area greater than 25 m 2 /g. The fact that the HpophiHc compound remains in highly dispersive ultra fine precipitate inside the minute pores of the absorbent support material is surprising.
- the precipitate may be constrained by the very smaU pore size and stabiHsed in ultra fine possibly amorphous form/s inside the channels.
- the HpophiHc drug may remain molecularly dispersed in a second component which is a membrane lipid and/ or surfactant.
- the ultra fine pores of the support material may be sufficient to physicaUy prevent or constrain crystallisation of the drug to larger crystals. Therefore it may only be necessary to make sure that the drug is deposited or absorbed as a solution into the pores of the support material in the first instance. The solvent, with or without the Hpid is removed, leaving behind an adsorbed material.
- primary loading is carried out by firstly impregnating the pores of a blank or unloaded support material with the compound associated in membrane Hpid and/ or surfactant, or dissolved in a solvent alone, which term includes aqueous media and mixtures thereof.
- the solvent is then removed using any appropriate drying method e.g. spray drying, vacuum, or freeze drying, etc., to obtain a loaded particulate composition.
- secondary loading may be carried out by firstly preparing a powder blend comprising the unloaded porous support material, compound with low water solubiHty and optionaUy membrane lipid and /or surfactant. In this method, the compound is loaded into the pores of the support medium foUowing addition of a suitable solvent/ solvent mixture.
- the composition obtained may be used as such as a free flowing powder or a Hquid suspension.
- the composition may also be further processed by extrusion into granules, and compacted into tablets by addition of suitable excipients commonly used in solid dosage forms.
- Organic and inorganic materials widely used as anti-caking agent, disintegrant, filler, adsorptive, pulverizing and moulding excipient may be used.
- the support material dissolves in the low pH conditions of the upper GI tract to release the compound in ultra fine form or in molecular dispersion.
- dissolution takes place inside the body after oral administration.
- the support material dissolves in the GI tract, releasing the HpophUic com- pound from the interior pores of the support material. If the compound is sequestered as a solution in Hpid, transfer into the surrounding medium wiU be instant. Even if it is not, because of the ultra fine form, dissolution wUl be much improved.
- a powder composition comprising the compound sequestered in ultra fine form in a support material may be further processed by contact with acid medium in a suit- able container. By this treatment the support material is dissolved and the HpophUic compound may be harvested or collected as ultra fine powder. The powder has improved solubiHty and dissolution profile and may be processed further into suitable dosage forms.
- a further embodiment of the invention relates to a mixture, e. g. a placebo mixture, suitable for the preparation of composition for improving the dispersibiHty of biologicaUy active compounds having low water solubUity, which comprises b) A porous particulate support material capable of incorporating within its pores the biologicaUy active compound; c) A membrane Hpid; or, in the alternative a membrane Hpid and/ or at least one pharmaceuticaUy or cosmeticaUy acceptable surfactant; and, optionaUy, d) Additional pharmaceuticaUy acceptable excipients.
- a mixture e. g. a placebo mixture, suitable for the preparation of composition for improving the dispersibiHty of biologicaUy active compounds having low water solubUity, which comprises b) A porous particulate support material capable of incorporating within its pores the biologicaUy active compound; c) A membrane Hpid; or, in the alternative a membrane Hpid and/ or at least one pharmaceuticaUy or cosmetic
- the mixture defined above comprises compositions, wherein the component b), the porous particulate support material, is present
- the mixture comprising the components b), c) and d) is obtainable by applying the above- mentioned methods and is suitable for secondary loading or dispersion of any agent of low water solubiHty, e.g. nutritional agents, vitamins, diagnostic agents or enzyme preparations.
- any agent of low water solubiHty e.g. nutritional agents, vitamins, diagnostic agents or enzyme preparations.
- a HIV protease inhibitor (MW: 516.2, empirical formula: C 20 Hi6Br 2 N6 ⁇ solubUity: ⁇ 0.010 ⁇ g/ml), and 70 mg of TPGS are dissolved by stirring in 105 g of a (25/75) mixture of ethanol 96% and dichloromethane.
- the solution is added in fractions under stirring to 7 g NEUSILIN Grade US2 (Fuji Chemicals).
- the addition of the fractions is repeated until complete addition of the solution to NEUSILIN.
- the solvent mixture is removed under vacuum for 180 min at room temperature after addition of each fraction.
- the resulting free flowing powder is fiUed into 25 gelatin capsules OO, each containing 300 mg of powder.
- the capsules are suitable for oral administration.
- porous maltodextrin (PineflowTM, Matsutani Chemical Industry Ltd) is equaUy suitable.
- the content of one capsule is added to one Hter of 0.1 M HCl in a dissolution apparatus as described in USP 24. After one hour stirring at 37°C ultra fine particles of HIV protease inhibitor is obtained.
- the HIV protease inhibitor is dissolved in a solution of 35 mg TPGS (instead of 70 mg TPGS), and VP 815, an enzyme modified soy Hpid with 60% monoacyl Hpid content (Lipoid KG, Ludwigshafen, FRG).
- cyclosporin A (Refarmed Chemical Ltd. Lugano, CH) is dissolved under stirring in 9.0 g ethanol 90%. The solution is added under stirring to 10 g NEUSILIN Grade US2 (Fuji Chemicals). The alcohol is removed under vacuum for 180 min at room temperature. The resulting free flowing powder is fiUed into 32 gelatin capsules OO, each containing 300 mg of powder.
- the capsules are suitable for oral administration.
- the content of one capsule is added to one Hter 0.1 M HCl containing 0.5% sodium dodecyl sulphate in a dissolution apparatus as described in USP 24 to one Hter 0.1 M HCl containing 0.5% sodium dodecyl sulphate. After one hour of stirring at 37° C an ultra fine suspension of cyclosporin particles is obtained.
- Example 5 lg cyclosporin A, practicaUy insoluble in water, (Refarmed Chemical Ltd. Lugano, CH) and 100 mg of Soybean lecithin S 75 (Lipoid KG, Ludwigshafen, FRG) are dissolved under stirring in 8.9 g ethanol 96%. The solution is added under stirring to 10 g NEUSILIN Grade US2 (Fuji Chemicals) The alcohol is removed under vacuum for 180 min at room temperature. The resulting free flowing powder is fiUed into 32 gelatin capsules OO, each containing 300 mg of powder. The capsules are suitable for oral administration. For characterisation purposes, the content of one capsule is added to one litre 0.1 M HCl in a dissolution apparatus as described in USP 24. Alter one hour stirring at 37° C an ultra fine dispersion of cyclosporin is obtained.
- Example 6 lg cyclosporin A, practicaUy insoluble in water, (Refarmed Chemical Ltd. Lugano, CH) and 3g VP 814 Soybean lecithin with 80% by weight monoacyl lecithin (Lipoid KG, Ludwigshafen, FRG) are dissolved in 6 g ethanol absolute.
- the Hpid solution is stirred into 10 g NEUSILIN Grade US2 (Fuji Chemicals).
- the alcohol is removed under vacuum for 180 min at room temperature.
- the resulting free flowing powder is fiUed into 32 gelatin capsules OO, each containing 300 mg of powder.
- the capsules are suitable for oral administration.
- the content of one capsule is added to one litre of 0.1 M HCl in a dissolution apparatus as described in USP 24. After one hour stirring at 37° C an ultra fine suspension of cyclosporine associated in Hpid particles is obtained.
- Examples 7, 8 and 9 are carried out in a manner similar to Examples 4, 5 and 6, but instead of 10 g NeusilinTM, 20 g of Fujicalin® Grade SG from Fuji Chemicals is used.
- Example 10
- a peripheral benzodiazepine receptor Hgand (MW: 394.86, empirical formula: C21H19C1N4O2, solubiHty: 1 ⁇ g/ml)
- TPGS d-Alpha Tocopheryl Polyethylene Glycol 1000 Succinate
- the resulting solution is loaded in stages to 2 g NeusilinTM Grade US2 from Fuji Chemicals.
- the solvent is removed under vacuum for 180 min at room temperature after addition of each fraction. This procedure was repeated until aU the solution was impregnated into Neusilin. This is an example based on primary loading as described.
- the resulting free flowing powder is fiUed into 6 gelatin capsules OO, each containing 300 mg of powder.
- the capsules are suitable for oral administration.
- the content of one capsule is added to one liter of 0.1 M HCl in a dissolution apparatus as described in USP 24. After one hour stirring at 37 ° C a finely dispersed suspension of HIV protease particles is obtained.
- DispersabUity of the loaded composition of Example 12 is compared with the drug alone (particle size ⁇ 10 ⁇ m) at a concentration of 0.1 mg/ml using 900 ml of 10 % w/v sodium dodecyl sulphate and 0.1 M HC in a 1 Htie dissolution beaker (USP XXIV) stirred with a paddle at 50 rpm at 37°C.
- the amount of drug exposed to the dissolution medium is three times lower than the maximum solubiHty of the drug substance.
- aHquots of the incubation media are taken and after fUtration through a 0.45 ⁇ m pores size fUter, drug concentration is determined using a specific HPLC method
- the dissolution rates of the two samples are iUustrated in Fig 1. It is seen that 96 wt % of the compound with low water solubiHty sequestered inside the pores of the porous support material disperses and dissolves within 6 min. compared to the drug alone which takes 45 min. under very similar conditions to reach the same level of dissolution.
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03734705A EP1476137A1 (en) | 2002-01-28 | 2003-01-28 | Composition comprising low water soluble compounds within porous carriers |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02250559 | 2002-01-28 | ||
EP02250559 | 2002-01-28 | ||
EP02257932 | 2002-11-18 | ||
EP02257932 | 2002-11-18 | ||
PCT/EP2003/000847 WO2003063835A1 (en) | 2002-01-28 | 2003-01-28 | Composition comprising low water soluble compounds within porous carriers |
EP03734705A EP1476137A1 (en) | 2002-01-28 | 2003-01-28 | Composition comprising low water soluble compounds within porous carriers |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1476137A1 true EP1476137A1 (en) | 2004-11-17 |
Family
ID=27664998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03734705A Ceased EP1476137A1 (en) | 2002-01-28 | 2003-01-28 | Composition comprising low water soluble compounds within porous carriers |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1476137A1 (en) |
WO (1) | WO2003063835A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1795183E (en) * | 2005-12-09 | 2009-08-21 | Teva Pharma | Aqueous dispersions and solutions of difficult to dissolve compounds and methods of their preparation |
JP2010512142A (en) * | 2005-12-22 | 2010-04-22 | ビーエーエスエフ ソシエタス・ヨーロピア | Method for producing vitamin E adsorbate |
EP2135601A1 (en) * | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
WO2011120530A1 (en) * | 2010-03-31 | 2011-10-06 | Lifecycle Phama A/S | Porous tablets as carriers for liquid formulations |
GB201008043D0 (en) * | 2010-05-14 | 2010-06-30 | Unilever Plc | Compositions |
CN110013467B (en) | 2018-01-10 | 2021-09-17 | 上海汉都医药科技有限公司 | Solid particle, preparation method thereof and pharmaceutical composition containing solid particle |
US20210169854A1 (en) | 2019-09-20 | 2021-06-10 | Novartis Ag | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation |
WO2022195545A1 (en) | 2021-03-18 | 2022-09-22 | Novartis Ag | Novel pharmaceutical formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62265234A (en) * | 1986-05-14 | 1987-11-18 | Showa Yakuhin Kako Kk | Preparation composition for suppressing bitterness |
JP2631890B2 (en) * | 1988-10-22 | 1997-07-16 | 日本特殊陶業株式会社 | Sustained drug-containing ceramic body and method of using same |
JPH05238930A (en) * | 1992-02-28 | 1993-09-17 | Eisai Co Ltd | Long-acting medicine |
GB9813906D0 (en) * | 1998-06-26 | 1998-08-26 | Isis Innovations Ltd | Coatings |
-
2003
- 2003-01-28 WO PCT/EP2003/000847 patent/WO2003063835A1/en not_active Application Discontinuation
- 2003-01-28 EP EP03734705A patent/EP1476137A1/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO03063835A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003063835A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1663468B1 (en) | Method for loading amphiphile particles with active agents | |
EP0954284B1 (en) | Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability | |
CA2119610C (en) | Process for the preparation of a liposome dispersion under elevated pressure conditions | |
EP1389089B1 (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
AU672793B2 (en) | Pharmaceutical composition containing cyclosporin derivative | |
WO1996037192A1 (en) | Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids | |
CA2162341A1 (en) | Pharmaceutical carriers | |
JP2002505307A (en) | Pharmaceutical compositions and uses thereof | |
EP0702562A1 (en) | Cyclosporin-containing powder composition | |
JP2007512373A (en) | Micellar system useful for delivery of lipophilic or hydrophobic compounds | |
HU226732B1 (en) | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent | |
JP2013532695A (en) | 6'-Fluoro- (N-methyl- or N, N-dimethyl-)-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4, b] A pharmaceutical dosage form comprising indole] -4-amine | |
AU777740B2 (en) | Pharmaceutical compositions for oral and topical administration | |
EP1476137A1 (en) | Composition comprising low water soluble compounds within porous carriers | |
KR101745489B1 (en) | Aqueous dispersed composition | |
CA2375371A1 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
US6251425B1 (en) | Glucoside paucilamellar vesicles | |
CA2333154C (en) | Microemulsion preconcentrates containing a piperidine substance p antagonist | |
CN113499343B (en) | Topical compositions | |
JPH0543450A (en) | Lyophilized formulation | |
CA2251194C (en) | Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability | |
EP1334718A1 (en) | Drug composition comprising dipeptydyl aldehyde derivative | |
kumar Nagabandi et al. | Silica-Lipid Hybrid Microparticles for Improved Bioavailability of Bcs Class IV Drugs | |
IL126384A (en) | Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability | |
AU2006201547A1 (en) | Pharmaceutical compostions for oral and topical administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040817 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
17Q | First examination report despatched |
Effective date: 20071017 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20120614 |